Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Nfocus Neuromedical.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Nfocus Neuromedical
ClinicalTrials.gov Identifier:
NCT01054391
First received: January 20, 2010
Last updated: NA
Last verified: January 2010
History: No changes posted

January 20, 2010
January 20, 2010
October 2008
December 2010   (final data collection date for primary outcome measure)
  • Proportion of subjects who show complete occlusion of target aneurysm or or fistula as judged by Core Laboratory radiologist by angiography [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Proportion of subjects who experience neurologic death or ipsilateral stroke [ Time Frame: 6 month follow-up ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae
NEC Trial - Nfocus - Neurovascular Embolization Cover for Treatment of Intracranial Aneurysms and Carotid/Vertebrobasilar Fistulae - A Non-Randomized Pilot Study

The purpose of this study is to determine whether the NEC device can effectively occlude the intracranial aneurysm or the carotid/vertebrobasilar fistula and maintain parent vessel patency

SAH (subarachnoid hemorrhage) is a devastating medical emergency. As many as 60% of patients who are afflicted die in the first 30 days as a result of the SAH, or remain severely disabled from the bleed. Existing treatment options include: medical management; endovascular therapy and surgical therapy. Endovascular techniques using detachable coils have now been refined to include stents which serve to prevent the coil mass from dislodging. Further improvement is believed to be possible with the NEC which creates a seal to exclude the aneurismal lumen from blood flow without the need for coils. This study involves the endovascular placement of the NEC across the aneurysm neck in order to treat a subset of aneurysms without coils.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Intracranial Aneurysms
  • Cavernous Carotid Fistula
  • Vertebrobasilar Fistula
Device: NEC - Neurovascular Embolization Cover
Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
Experimental: NEC Arm
Utilization of NEC (Neurovascular Embolization Cover) for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistulae
Intervention: Device: NEC - Neurovascular Embolization Cover
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
Not Provided
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of unruptured aneurysm OR ruptured aneurysm in clinically stable patients in whom coils alone are not an efficient treatment in the opinion of the investigator (i.e., large neck or fusiform aneurysm) OR direct fistulae (Type A - traumatic or aneurismal) and indirect if dural branches come from the internal carotid or vertebral artery and cannot be embolized selectively
  • Subject has a confirmed diagnosis of an intracranial (including intracavernous and intrapetrous regions) sidewall saccular aneurysm or carotid vertebrobasilar fistula
  • Parent artery reference diameter is >2.5mm and <4.5mm
  • Subject is an adult above age 18
  • Subject is able to provide written Informed Consent
  • Subject has good general health, is clinically stable, and is considered to be mentally sound
  • Subject is able and is willing to meet all expected requirements of the clinical protocol, including attending the scheduled follow-up examinations for the duration of this trial.

Exclusion Criteria:

  • Subject has subarachnoid hemorrhage (SAH) < three (3) weeks prior to NEC procedure
  • Subject has had prior stenting of the target aneurysm.
  • Subject is contraindicated for antiplatelet therapy,anticoagulant therapy, or radiographic contrast media.
  • Subject has collagen vascular disease.
  • Subject has a contraindication to angiography (e.g., serum creatinine level > 2.5 mg/dL)
  • Subject has evidence of active infection at the time of treatment
  • Subject is pregnant or breastfeeding or unwilling to use birth control for duration of study
  • Subject has participated in a study involving an investigational drug or device within 30 days prior to proposed entry into subject study
  • Subject is unable to comply with study procedures or protocol
  • Subject has co-morbid disease or condition expected to compromise survival or ability to complete follow-up assessments to 180 days
Both
19 Years to 80 Years
No
Germany
 
NCT01054391
NEC001
Not Provided
Tom Ross, Vice-President, Nfocus Neuromedical Inc
Nfocus Neuromedical
Not Provided
Principal Investigator: Olav Jansen, Prof. Dr. med. Universitatsklinikum Schleswig-Holstein Campus Kiel Institut fur Neuroradiologie
Nfocus Neuromedical
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP